Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.

Vogt WB, Joyce G, Xia J, Dirani R, Wan G, Goldman DP.

Health Aff (Millwood). 2011 Dec;30(12):2346-54. doi: 10.1377/hlthaff.2010.1296.

2.

Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.

Law MR, Ross-Degnan D, Soumerai SB.

Psychiatr Serv. 2008 May;59(5):540-6. doi: 10.1176/appi.ps.59.5.540.

PMID:
18451014
3.

Medicaid prior authorization policies and imprisonment among patients with schizophrenia.

Goldman D, Fastenau J, Dirani R, Helland E, Joyce G, Conrad R, Lakdawalla D.

Am J Manag Care. 2014 Jul;20(7):577-86.

4.

Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA.

Clin Ther. 2008 Aug;30(8):1524-39; discussion 1506-7. doi: 10.1016/j.clinthera.2008.08.009.

PMID:
18803994
5.

Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.

Law MR, Lu CY, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2010 Apr;32(4):729-41; discussion 716. doi: 10.1016/j.clinthera.2010.04.007.

6.

Medicaid's prior authorization program and access to atypical antipsychotic medications.

Polinski JM, Wang PS, Fischer MA.

Health Aff (Millwood). 2007 May-Jun;26(3):750-60.

7.

Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness.

Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS.

Med Care. 2010 Jan;48(1):4-9. doi: 10.1097/MLR.0b013e3181bd4c10.

PMID:
19956079
8.

Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.

Walthour A, Seymour L, Tackett R, Perri M.

Ann Pharmacother. 2010 May;44(5):809-18. doi: 10.1345/aph.1M620.

PMID:
20388858
9.

The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Stein BD, Leckman-Westin E, Okeke E, Scharf DM, Sorbero M, Chen Q, Chor KH, Finnerty M, Wisdom JP.

J Child Adolesc Psychopharmacol. 2014 Sep;24(7):374-81. doi: 10.1089/cap.2014.0008.

11.

Atypical antipsychotics: considerations for Medicaid coverage.

Surles RC.

Am J Manag Care. 2005 Sep;11(8 Suppl):S248-53.

13.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
14.

Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.

Seabury SA, Goldman DP, Kalsekar I, Sheehan JJ, Laubmeier K, Lakdawalla DN.

Am J Manag Care. 2014 Feb 1;20(2):e52-60.

15.

Effects of antipsychotic medication on psychiatric service utilization and cost.

Rothbard A, Murrin MR, Jordan N, Kuno E, McFarland BH, Stroup TS, Morrissey JP, Stiles PG, Boothroyd RA, Merwin E, Shern DL.

J Ment Health Policy Econ. 2005 Jun;8(2):83-93.

PMID:
15998980
16.

Medicaid policies to contain psychiatric drug costs.

Koyanagi C, Forquer S, Alfano E.

Health Aff (Millwood). 2005 Mar-Apr;24(2):536-44. Review.

17.

Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.

Fischer MA, Schneeweiss S, Avorn J, Solomon DH.

N Engl J Med. 2004 Nov 18;351(21):2187-94.

18.

Differences in the cost of antidepressants across state Medicaid programs.

Kelton CM, Rebelein RP, Heaton PC, Ferrand Y, Guo JJ.

J Ment Health Policy Econ. 2008 Mar;11(1):33-47.

PMID:
18424875
19.

Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder.

Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB.

Psychiatr Serv. 2009 Apr;60(4):520-7. doi: 10.1176/appi.ps.60.4.520.

PMID:
19339328
20.

Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.

Lu CY, Law MR, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2011 Jan;33(1):135-44. doi: 10.1016/j.clinthera.2011.01.012.

Items per page

Supplemental Content

Support Center